A randomised, double-blind, crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in patients with post-herpetic neuralgia
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2014
At a glance
- Drugs CNV 2197944 (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Convergence Pharmaceuticals
- 10 May 2014 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 28 Jan 2014 Planned End Date changed from 1 Apr 2014 to 1 Jun 2014.